Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival

Journal of the American Society of Nephrology

Volumn 24, Issue 12, 2013, Pages 2071-2080

  Lambie, Mark ^a   Chess, James ^b,c   Donovan, Kieron L ^b   Kim, Yong Lim ^d   Do, Jun Young ^e   Lee, Hi Bahl ^f   Noh, Hyunjin ^f   Williams, Paul F ^g,h   Williams, Andrew J ^c   Davison, Sara ⁱ   Dorval, Marc ^j   Summers, Angela ^k   Williams, John D ^b   Bankart, John ^a   Davies, Simon J ^a   Topley, Nicholas ^b  

^a KEELE UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c MORRISTON HOSPITAL   (United Kingdom)

^d Kyungpook National University Hospital   (South Korea)

^e Young Nam University Hospital   (South Korea)

^f Soonchunhyang University   (South Korea)

^g IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

^h CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j Dr Georges L Dumont University Hospital Centre   (Canada)

^k MANCHESTER ROYAL INFIRMARY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GAMMA INTERFERON; HEMOGLOBIN; ICODEXTRIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CANADA; COMORBIDITY; CYTOKINE PRODUCTION; DEMOGRAPHY; DIALYSATE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFLAMMATION; INTRAPERITONEAL INFLAMMATION; KOREA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERITONEAL DIALYSIS; PERITONEUM; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL; SYSTEMIC INFLAMMATION; TREATMENT DURATION; ULTRAFILTRATION; UNITED KINGDOM; URINE VOLUME; BLOOD; COHORT ANALYSIS; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERITONITIS; PREDICTIVE VALUE;

ADULT; AGED; COHORT STUDIES; COMORBIDITY; CYTOKINES; FEMALE; HUMANS; INCIDENCE; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; PREDICTIVE VALUE OF TESTS; PREVALENCE;

EID: 84888987538     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013030314     Document Type: Article

References (34)

1. Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG: Metaanalysis: Peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 17: 2591-2598, 2006
2. Asghar RB, Davies SJ: Pathways of fluid transport and reabsorption across the peritoneal membrane. Kidney Int 73: 1048-1053, 2008
3. Chung SH, Heimbürger O, Stenvinkel P, Qureshi AR, Lindholm B: Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant 18: 590-597, 2003
4. Davies SJ, Phillips L, Naish PF, Russell GI: Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 17: 1085-1092, 2002
5. Davies SJ, Bryan J, Phillips L, Russell GI: Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 11: 498-506, 1996
6. Parikova A, Smit W, Struijk DG, Krediet RT: Analysis of fluid transport pathways and their determinants in peritoneal dialysis patients with ultrafiltration failure. Kidney Int 70: 1988-1994, 2006
7. LambieML, John B,Mushahar L, Huckvale C, Davies SJ: The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney Int 78: 611-618, 2010
8. Pecoits-Filho R, CarvalhoMJ, Stenvinkel P, LindholmB, HeimbürgerO: Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 26: 53-63, 2006
9. Oh KH, Jung JY, Yoon MO, Song A, Lee H, Ro H, Hwang YH, Kim DK, Margetts P, Ahn C: Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transplant 25: 1639-1646, 2010
10. Gillerot G, Goffin E, Michel C, Evenepoel P, Biesen WV, Tintillier M, Stenvinkel P,HeimbürgerO, LindholmB, Nordfors L, Robert A,Devuyst O: Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int 67: 2477-2487, 2005
11. Hwang YH, SonMJ, Yang J, Kim K, ChungW, JooKW, KimY, Ahn C,Oh KH: Effects of interleukin-6 T15A single nucleotide polymorphism on baseline peritoneal solute transport rate in incident peritoneal dialysis patients. Perit Dial Int 29: 81-88, 2009
12. Verduijn M, Maréchal C, Coester AM, Sampimon DE, Boeschoten EW, Dekker FW,Goffin E, Krediet RT, DevuystO: The -174G/C variant of IL6 as risk factor for mortality and technique failure in a large cohort of peritoneal dialysis patients. Nephrol Dial Transplant 27: 3516-3523, 2012
13. Perl J, Huckvale K, Chellar M, John B, Davies SJ: Peritoneal protein clearance and not peritoneal membrane transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. Clin J Am Soc Nephrol 4: 1201-1206, 2009
14. Yang X, Fang W, Bargman JM, Oreopoulos DG: High peritoneal permeability is not associated with higher mortality or technique failure in patients on automated peritoneal dialysis. Perit Dial Int 28: 82-92, 2008
15. Johnson DW, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, Bannister KM, Badve SV: Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 25: 1973-1979, 2010
16. Martikainen T, Ekstrand A, Honkanen E, Teppo AM, Grönhagen-Riska C: Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function? A 1-year follow-up study. Scand J Urol Nephrol 39: 410-416, 2005
17. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Pagé D; The Canada-USA (CANUSA) Peritoneal Dialysis Study Group: Increased peritonealmembrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. J Am Soc Nephrol 9: 1285-1292, 1998
18. Rumpsfeld M, McDonald SP, Purdie DM, Collins J, Johnson DW: Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients. Am J Kidney Dis 43: 492-501, 2004
19. Davies SJ: Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int 66: 2437-2445, 2004
20. Struijk DG, Krediet RT, Koomen GCM, Boeschoten EW, Hoek FJ, Arisz L: A prospective study of peritoneal transport in CAPD patients. Kidney Int 45: 1739-1744, 1994
21. Johnson DW, Mudge DW, Blizzard S, Arndt M, O'Shea A, Watt R, Hamilton J, Cottingham S, Isbel NM, Hawley CM: A comparison of peritoneal equilibration tests performed 1 and 4 weeks after PD commencement. Perit Dial Int 24: 460-465, 2004
22. Lui SL, Yung S, Yim A, Wong KM, Tong KL, Wong KS, Li CS, Au TC, Lo WK, Ho YW, Ng F, Tang C, Chan TM: A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: A randomized clinical trial. Am J Kidney Dis 60: 966-975, 2012
23. le Poole CY, Welten AG, ter Wee PM, Paauw NJ, Djorai AN, Valentijn RM, Beelen RH, van den Born J, van Ittersum FJ: A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation. Perit Dial Int 32: 305-315, 2012
24. Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi MG, Tan SH, Voss D: on behalf of the balANZ Trial Investigators. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: The balANZ trial. Nephrol Dial Transplant 27: 4445-4453, 2012
25. TopleyN, Jörres A, LuttmannW, PetersenMM, LangMJ, Thierauch KH, Müller C, Coles GA, Davies M, Williams JD: Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1 beta and TNF alpha. Kidney Int 43: 226-233, 1993
26. Opatrna S, Lysak D, Trefil L, Parker C, Topley N: Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/ lactate-based peritoneal dialysis solutions. Perit Dial Int 32: 37-44, 2012
27. Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS: Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 45: 324-333, 2005
28. Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 16[Suppl 1]: S83-S88, 2005
29. Meuwese CL, Snaedal S, Halbesma N, Stenvinkel P, Dekker FW, Qureshi AR, Barany P, Heimburger O, Lindholm B, Krediet RT, Boeschoten EW, Carrero JJ: Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-a are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant 26: 1313- 1318, 2011
30. Zemel D, Imholz AL, de Waart DR, Dinkla C, Struijk DG, Krediet RT: Appearance of tumor necrosis factor-a and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 46: 1422-1430, 1994
31. Yu Z, Tan BK, Dainty S, Mattey DL, Davies SJ: Hypoalbuminaemia, systemic albumin leak and endothelial dysfunction in peritoneal dialysis patients. Nephrol Dial Transplant 27: 4437-4445, 2012
32. Lopes Barreto D, Coester AM, Noordzij M, Smit W, Struijk DG, Rogers S, de Waart DR, Krediet RT: Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients.Nephrol Dial Transplant 26: 3739-3744, 2011
33. Rippe B: A three-pore model of peritoneal transport. Perit Dial Int 13 [Suppl 2]: S35-S38, 1993
34. Rasbash J, Charlton C, Browne WJ, Healy M, Cameron B: MLwiN Version 2.1, Centre for Multilevel Modelling, University of Bristol, 2009